FANDOFLOXACIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H18F2N4O3
Molecular Weight	400.3787
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CCN(CC1)C2=CC3=C(C=C2F)C(=O)C(=CN3C4=NC=C(F)C=C4)C(O)=O

InChI

InChIKey=AWCAUUQZTXYMPB-UHFFFAOYSA-N

InChI=1S/C20H18F2N4O3/c1-24-4-6-25(7-5-24)17-9-16-13(8-15(17)22)19(27)14(20(28)29)11-26(16)18-3-2-12(21)10-23-18/h2-3,8-11H,4-7H2,1H3,(H,28,29)

HIDE SMILES / InChI

Description
Sources: http://125.60.48.13/home4/dl_files/edu/001/IM1199900199.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9145377 | https://www.ncbi.nlm.nih.gov/pubmed/9145824 | http://adisinsight.springer.com/drugs/800004009

Fandofloxacin is a difluoroquinolone derivative. This compound possesses an antibacterial spectrum comparable to those of rufloxacin and ciprofloxacin in vivo. Fandofloxacin showed a rapid and nearly complete absorption, and a long residence time in the body. Because it has been reported that the in vivo antibacterial activity of Fandofloxacin is comparable or superior to other quinolones, despite the fact that its in vitro activity is significantly lower than that of the other compounds, the pharmacokinetics of this antibiotic may be responsible, at least in part, for the enhanced in vivo antibacterial activity of Fandofloxacin. Fandofloxacin is an inhibitor of bacterial DNA gyrase. The toxicities and adverse effects of Fandofloxacin observed in various toxicology studies and clinical trials were less than those of commercially available drugs. It has been in phase II clinical trial for the treatment of Urinary tract infections. However, this research has been discontinued in 2008.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial DNA gyrase 66 Target ID: CHEMBL2311224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9875449 \| http://adisinsight.springer.com/drugs/800004009	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Urinary tract infections 205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9145377	Curative		Phase II 1132	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
7.36 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.47 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
5.65 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
107.4 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
114.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
82.2 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
87.7 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
17.15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
16.74 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
18.34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
17.54 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Analyte	Population
50% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
50% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
50% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
50% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9786475	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	FANDOFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L435P
BOC Sciences	164150-99-6	https://www.bocsci.com/fandofloxacin-cas-164150-99-6-item-65165.html

PubMed

Title	Date	PubMed
Pharmacokinetic study of a new quinolone, DW-116.	1995	8549349
In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.	1997 Apr	9145824
Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats.	1997 May	9145377
Developmental toxicity assessment of the new fluoroquinolone antibacterial DW-116 in rabbits.	2005 Jan-Feb	15669036

Patents

Sample Use Guides

In Vivo Use Guide

400 mg tablet once daily

Route of Administration: Oral

In Vitro Use Guide

Against S.pyogenes, Fandofloxacin (DW-116) (MIC50=2 mg/L; MIC90=4 mg/L) was two- or four-fold more active than rufloxacin (MIC50=8 mg/L; MIC90=8 mg/L) and it exhibited similar activity to sparfloxacin, ciprofloxacin and ofloxacin. DW-116 (MIC50=4–8 mg/L; MIC90=8–32 mg/L) was more active than rufloxacin (MIC50=4–16 mg/L; MIC90=16–32 mg/L) and less active than sparfloxacin and ciprofloxacin against S. pneumoniae and Enterococcus faecalis. Antibacterial activity of DW-116 against E. coli (MIC range 0.25–32 mg/L) was slightly inferior to that of sparfloxacin (MIC range 0.03–4 mg/L), ciprofloxacin (MIC range < 0.008–1 mg/L) and ofloxacin (MIC range 0.015–16 mg/L) and similar to that of rufloxacin (MIC range 0.25–32 mg/L).

Name

Type

Language

FANDOFLOXACIN

Official Name

English

6-FLUORO-1-(5-FLUORO-2-PYRIDYL)-1,4-DIHYDRO-7-(4-METHYL-1-PIPERAZINYL)-4-OXO-3-QUINOLINECARBOXYLIC ACID

Systematic Name

English

fandofloxacin [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C795